To restrict access to therapy with JUXTAPID to patients with a clinical or laboratory diagnosis consistent with HoFH.

FORBES: FDA Approves Lomitapide For Homozygous Familial Hypercholesterolemia

To restrict access to therapy with KYNAMRO to patients with a clinical or laboratory diagnosis consistent with homozygous familial hypercholesterolemia (HoFH).

FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia